Siloton’s Post

Long-Term Changes of Urinary Exosomal Peptide Levels After Thyroidectomy in Patients with Thyroid Cancer: A Prospective Observational Study Long-Term Changes of Urinary Exosomal Peptide Levels After Thyroidectomy in Patients with Thyroid Cancer: A Prospective Observational Study ABSTRACT The study aimed to investigate the potential of urine exosomal peptide levels to predict the risk of thyroid cancer recurrence after thyroidectomy. METHODS Patients newly diagnosed with papillary thyroid cancer and who had undergone thyroidectomy were included. Urine samples were collected at 12 months and 24 months after enrollment, and urine exosomes containing different peptides were analyzed. RESULTS 70 patients were enrolled, categorized by the time interval between surgery and enrollment. No recurrences were observed during the 2-year follow-up. No significant differences were found in serum proteins or urine exosomal peptides between groups or time intervals. Known risk factors for high-risk thyroid cancer showed only mild correlation with serum protein levels and urine exosomal peptides. CONCLUSION The study revealed the long-term fluctuation ranges of serum proteins and urine exosomal peptides in thyroid cancer patients post-thyroidectomy. Concentrations of serum proteins or urine exosomal peptides within certain ranges may indicate a lower risk of thyroid cancer recurrence in high-risk patients. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03488134. PMID: 38803995 | PMC: PMC11129743 | DOI: 10.2147/IJN.S458931 Clinical trials are key to developing safe and effective treatments. It’s important to extend their benefits into everyday medical practice. DocSym, our AI-driven platform, helps by consolidating ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians. In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows and improve patient outcomes, reduce paper routine. Learn more about how we can help at aidevmd.com. https://lnkd.in/gAru9228 #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

MSC-Derived Exosome Therapy: Advances and Clinical Trial Outcomes "The Rising Star of Regenerative Medicine: MSC-Derived Exosomes" Mesenchymal Stem Cell (MSC)-derived exosomes represent a major advancement in regenerative medicine, offering a non-cellular method for treating diverse diseases. These vesicles facilitate intercellular communication and support biological processes essential for regeneration by transporting proteins, RNA, and miRNAs. Key Clinical Trials 1.Chronic Kidney Disease (CKD): A trial in Egypt tested umbilical cord blood-derived MSC exosomes in a randomized, placebo-controlled setup, revealing their efficacy in slowing CKD progression. Patients received bi-weekly doses, improving renal function and decelerating the disease. 2.Cardiovascular Disease: This study combined MSC-derived exosomes with autologous mitochondrial transplantation in coronary artery bypass graft surgery, enhancing myocardial function and reducing complications, suggesting a new approach for cardiac repair. 3.Preeclampsia: Focusing on endothelial dysfunction in preeclampsia, MSC-derived exosomes improved placental health and maternal outcomes by promoting angiogenesis and enhancing endothelial cell function. Technological Progress 2024 also brought advancements in exosome isolation and characterization. Ultracentrifugation remains standard, while Tangential Flow Filtration (TFF) has gained importance for its efficiency and scalability. Challenges and Future Directions Despite successful clinical outcomes, issues like scalability and long-term safety persist, necessitating further innovation and comprehensive safety studies. Regulatory approvals also remain complex. Conclusion The 2024 clinical trials have deepened our understanding of MSC-derived exosome therapy, underscoring its potential in treating various conditions. Overcoming current challenges will be crucial for integrating these therapies into mainstream medical practice, providing new treatments for previously intractable conditions. Source : https://lnkd.in/dbkPK6mG #RegenerativeMedicine #MSCExosomes #ClinicalTrials2024 #StemCellResearch #HealthcareInnovation #Fibula #FibulaHEALTH #FibulaClinicalResearch #FibulaCRO #Health #Medical #Surgery #Oncology #Hematology #Immunology #Cartcell #Crispr #Cancer #CancerSurgery #Kanser #ClinicalResearch #ClinicalTrials #Pharma #who #CRO #Healthcare #WorldCancerDay #FightCancer #ClinicalTrials #CancerAwareness #CancerResearch #CancerCare #CancerPrevention #CancerTreatment #HealthEducation #GlobalSolidarity #InnovativeTreatments #CancerSurvivorship #CancerWarriors #BeatCancer

This is the future of medicine is that the best practitioners and highly sort after practitioners will move into jurisdictions that suppprt this type Of research and clinical trials and advance regenerative and orthobiologcal treatments.

It has been very exciting news for Mayo Clinic secures Advanced Research Projects Agency for Health (ARPA-H) award to build a living pharmacy within the body for inflammatory disease: The award for up to $42.8 million. Rochester, Minn. — Mayo Clinic is the prime site for an ARPA-H award to develop an implantable device that acts as a living pharmacy, triggering a "cell factory" in the body to treat inflammatory disease. ARPA-H, short for Advanced Research Projects Agency for Health, is an agency within the Department of Health and Human Services. It supports research for potentially transformative biomedical and health breakthroughs. The award for up to $42.8 million for Engage Assess SecretE (EASE): A Platform for Treating Chronic Inflammation is aimed at creating a revolutionary treatment for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Eventually, the hope is to use it for disorders related to an overactive immune system, such as rheumatoid arthritis and psoriasis. "I am very excited that this project has high societal impact and patient relevance. It represents a prime example of convergence science, where clinicians, biologists and engineers come together to produce a sophisticated solution to improve patient care," says Alexander Revzin, Ph.D., a biomedical engineer and scientist at Mayo Clinic who is the principal investigator for EASE. The researchers aim to develop a bioelectric device that carries genetically engineered cells to generate monoclonal antibodies to overcome the challenges of inflammatory disease. The high-tech gadget would be implanted in an outpatient procedure. "It's a futuristic device that encapsulates living cells in a protective membrane to ensure long-term survival. The device will also have the ability to prompt living cells to release biotherapeutic molecules, which, in this case, is monoclonal antibodies," says Suman Bose, Ph.D., a biomedical engineer at Mayo Clinic in Arizona. Monoclonal antibodies are engineered to target specific proteins involved in the inflammatory process, helping to reduce inflammation and manage symptoms of IBD. https://lnkd.in/egt6JRx2

Innovations in STEMI Treatment Approaches Acute ST-segment elevation myocardial infarction (STEMI) remains a significant cause of morbidity & mortality worldwide. The urgency treatment stems from the necessity to restore coronary blood flow promptly to minimize myocardial damage & improve patient outcomes. The Evolution The cornerstone of treatment has been rapid reperfusion therapy, primarily through primary percutaneous coronary intervention PPCI or thrombolytic therapy. These methods have significantly improved outcomes over the past, recent advancements have introduced novel techniques & enhanced existing protocols, improving survival rates & quality of life for STEMI patients. High-Sensitivity Troponins: assays have revolutionized by allowing the detection of MI with greater precision & speed to identify STEMI at an earlier stage, facilitating quicker decision-making & intervention. Advanced Imaging Techniques: such as cardiac MRI & CT, has enhanced the diagnosis and management of STEMI, providing info about myocardial viability, perfusion & the extent of infarction, aiding in the customization of treatment plans. For instance, cardiac MRI can help identify patients who would benefit most from specific interventions, optimizing resource utilization & improving outcomes. 1- Enhanced Reperfusion Strategies: emerged to improve outcomes further, while PPCI remains the gold standard *Pharmacoinvasive Therapy: Combining pharmacological agents with mechanical reperfusion techniques, has shown promise in scenarios where immediate PPCI is not feasible. *Thrombectomy Devices: The advanced devices has improved the ability to remove thrombus burden effectively, enhancing reperfusion quality & reducing distal embolization. *Bioresorbable Vascular Scaffolds: provide temporary vessel support & gradually dissolve, potentially reducing long-term complications associated with permanent implants. 2-Adjunctive Therapies: play a crucial role in STEMI management, aiming to protect the myocardium and improve patient outcomes: *TherOx SSO2 Supersaturated oxygen Therapy: delivered directly to the coronary arteries, has potential in reducing infarct size and improving cardiac function. This innovative therapy enhances oxygen delivery to ischemic tissue, promoting myocardial salvage. *Hypothermia/targeted temperature management can help reduce myocardial damage by lowering the metabolic rate of the heart, techniques have shown promise in experimental studies & clinical trials. *Anti-inflammatory Agents: Inflammation plays a significant role in the pathogenesis of myocardial injury. Targeting inflammatory pathways with novel agents to mitigate myocardial damage and improve outcomes. 3-Personalized Medicine & Genetic Insights Their integration insights into STEMI treatment by understanding predispositions & variations in response to therapies, clinicians can tailor treatment plans more effectively. #cardiacMRI #STEMI #TherOx #SSO2 #PCI #HealingHearts

🌟 Exosomes as Biomarkers: A New Frontier in Diagnostics and Personalized Medicine🌟 In the rapidly evolving field of medical diagnostics, **exosomes** are emerging as a revolutionary tool. These small extracellular vesicles, secreted by cells, carry a variety of proteins, lipids, and nucleic acids (such as mRNA, miRNA, and DNA) that reflect the physiological and pathological status of their parent cells. This makes them highly valuable as biomarkers for diagnosing and monitoring diseases. 1. Non-Invasive Diagnostics: One of the main advantages of exosomes as biomarkers is their presence in easily accessible biological fluids such as blood, urine, saliva, and cerebrospinal fluid. This enables non-invasive or minimally invasive diagnostic procedures, offering a stark contrast to traditional biopsies, which are often invasive and uncomfortable for patients. 2. Real-Time Disease Monitoring: Exosomes in body fluids carry molecular signatures that reflect the status of tissues, including tumors. This allows for real-time monitoring of disease progression or treatment response. For instance, in cancer, tumor-derived exosomes (TDEs) carry oncogenic proteins, miRNAs, and DNA fragments detectable in the bloodstream. These exosomes provide insights into tumor heterogeneity and metastasis, helping clinicians monitor disease progression, detect early recurrence, or evaluate treatment efficacy. 3. Immune System Insights: Exosomes from immune cells can serve as biomarkers for autoimmune or inflammatory diseases because they carry molecules that reflect immune status. This can be crucial for diagnosing and managing conditions like rheumatoid arthritis, lupus, and multiple sclerosis. 4. Prognostic Tools: Exosomes also show promise as prognostic tools, predicting the likelihood of disease recurrence or treatment response. For example, specific miRNA profiles in exosomes have been associated with chemotherapy resistance in cancer patients, allowing clinicians to adjust treatment plans accordingly. 5. Personalized Medicine: The ability of exosomes to provide real-time information about disease status and treatment response is transforming the landscape of personalized medicine. By tailoring treatments based on the molecular signatures carried by exosomes, healthcare providers can offer more effective and individualized care. 🔬Exosomes are not just a breakthrough in diagnostics; they are a powerful tool for personalized medicine. #Exosomes #Biomarkers #Diagnostics #PersonalizedMedicine #HealthcareInnovation #MedicalResearch #MedicalLaboratoryTechnology #Microbiology #Phlebotomy #LaboratoryTesting #DiagnosticTesting #HealthcareProfessional #MedicalTesting #ClinicalLaboratory #BiomedicalScience #HealthcareIndustry #MedicalScience #LaboratoryMedicine #ClinicalMicrobiology #InfectionControl #PhlebotomyTechnician #MedicalLabTechnician #MicrobiologyLab #ClinicalLab #HealthcareCareer #MedicalCareer #ScienceCareer #COVID19Testing #Virology #Bacteriology

A Hot-off-the-Press Publication: Landmark Review of Umbilical Cord and Wharton's Jelly Mesenchymal Stem Cell Therapies As a physician in the field of regenerative medicine, I believe this is definitely a must-read review regarding the latest advances in stem cell therapies and their applications, that covers both preclinical and clinical studies, providing a thorough analysis of the therapeutic potential of UC-MSCs and WJ-MSCs. The authors provide thorough descriptions into the mechanisms by which these stem cells and their extracellular vesicles (EVs) exert their therapeutic effects, including immunomodulation, anti-inflammatory properties, and promotion of tissue regeneration, making it a robust and up-to-date review. In addition, the immune-privileged status of UC-MSCs and WJ-MSCs with minimal ethical concerns highlights their superiority over other stem cell sources. Speaking of key aspects: In the area of bone and cartilage regeneration, UC-MSCs and WJ-MSCs enhance osteocalcin synthesis and inhibit osteoclast activity, thus showing promise in the treatment of osteoarthritis. Similarly, in liver and kidney diseases, UC-MSCs can differentiate into hepatocyte-like cells to reduce liver fibrosis, while WJ-MSCs improve kidney function by reducing renal fibrosis. Furthermore, in neurological disorders, UC-MSCs and WJ-MSCs offer neuroprotection for conditions such as Parkinson's, Alzheimer's, and spinal cord injuries by modulating neuroinflammation and promoting neuronal regeneration. In cardiovascular health, these stem cells exhibit anti-apoptotic and anti-fibrotic effects, which are beneficial in treating myocardial infarction and heart failure. This review provides clear and evidence-based understanding of UC-MSCs and WJ-MSCs, and even potential real-world clinical practices, through as-current-as-it-gets data on both published and still in-progress trials. Through research driven by innovation toward therapies that improve longevity and well-being, quality of life remains a top priority. Join us at RMI in advancing the frontier of regenerative medicine. #RegenerativeMedicine #StemCellTherapy #ClinicalResearch #HealthcareInnovation #MedicalScience #TissueEngineering

Promising research on using stemcells to repair lung damage from COPD - can they restore breathing function? New article from Stem Cell Medical Center explores the science behind using cell therapy to heal COPD patients. Suffocating lung conditions like COPD may have new hope. Innovations in umbilical cord cell therapy are showing the ability to reduce inflammation, improve quality of life, and potentially regenerate damaged lung structures. Early clinical trials indicate that concentrated stem cell doses could halt the progressive lung capacity decline that defines worsening COPD. Read Stem Cell Medical Center's full article for the latest evidence that the healing power of stem cells may treat this chronic illness. Click to learn more about our COPD stem cell treatments and regenerative expertise! Read the full article here: https://lnkd.in/gnM5MF5T #COPD #stemcells #celltherapy #lunghealth

TIL about the "Platform Trial," a more strategic and efficient way of conducting clinical research. While not perfect for all trials, what immediately resonated with me was how this approach brings bigger picture thinking to how researchers can best focus their efforts on helping patient groups with unmet needs. Models exist in Stroke, ALS, Chemotherapy, Chronic Pain. In 2021, "NIH & National Institute of Neurological Disorders and Stroke (NINDS) issued a notice of special interest (NOSI) for establishing an endovascular thrombectomy platform trial as a module within the NIH-funded StrokeNet." Seems like this could be a great opportunity to advance how #neurotech devices and #CNS trials work for patient communities. What am I missing? What do I need to know? I'd love to learn more if anybody can point me to certain initiatives or experts in this space. h/t Brock Vendsel WHAT IS A PLATFORM TRIAL? First developed for cancer chemotherapy, platform or master trials represent a new approach for these situations. They allow enrollment into multiple different arms and use novel statistic approaches (Bayesian prediction models, response-adaptive randomization schemes) to allow these arms to be terminated early for futility or benefit, new arms to be added, and, potentially, for information to be shared across treatment arms. For example, any given patient with any given type of cancer would be enrolled into one of several different experimental arms or in the control group. These patients can serve as controls for multiple different arms. In addition, trial infrastructure at clinical sites and for central administration does not shut down at the conclusion of a study arm. This creates great flexibility and efficiency in terms of resource use and time to conclusion. Because of its success in oncology, platform trials have begun in other diseases as well, such as amyotrophic lateral sclerosis and chronic pain. https://lnkd.in/gmrmjbdX

𝐀 𝐍𝐞𝐰 𝐇𝐨𝐩𝐞 𝐟𝐨𝐫 𝐋𝐢𝐯𝐞𝐫 𝐂𝐢𝐫𝐫𝐡𝐨𝐬𝐢𝐬: 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐏𝐫𝐨𝐦𝐢𝐬𝐞 𝐨𝐟 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 Liver cirrhosis, a severe condition characterized by permanent scarring and impaired liver function, has long been a significant health issue worldwide. Traditionally, treatment options for cirrhosis have been limited, expensive, and often impact patients' quality of life. However, groundbreaking advancements in stem cell therapy offer a promising alternative, providing hope for patients suffering from this debilitating disease. Primary causes of liver cirrhosis include chronic alcohol abuse and hepatitis B and C infections. In the early stages, the liver attempts to repair itself, but as the condition worsens, this self-repair becomes increasingly difficult. Advanced cirrhosis often results in irreversible liver damage. Stem cell treatment presents a new approach to tackling liver cirrhosis, addressing the limitations of conventional treatments while offering a safer and more effective option. Recent studies highlight the therapeutic properties of stem cells and their potential in healing liver disease. Clinical trials on mice have shown that stem cells can repair damaged liver tissues, accelerating the recovery of liver function. A systematic review further supports the efficacy of mesenchymal stem cells in treating liver cirrhosis, yielding better clinical outcomes than traditional treatments. Patients undergoing stem cell therapy for liver cirrhosis can expect observable results within four to six months. The process involves intravenous infusion, allowing the new cells to travel through the bloodstream and replace scarred tissues in the liver. As the treatment progresses, patients typically experience improvements in appetite, reduced fatigue, and diminished swelling in the legs, feet, or ankles. As research continues, we can expect further advancements and refinements in this promising field, ultimately leading to better outcomes and improved quality of life for those affected by this debilitating condition. With its potential to revolutionize the treatment of liver cirrhosis, stem cell therapy offers a beacon of hope to patients and medical professionals alike. Image Source: Medical XPress #CellnCo #WorldAutismAwarenessDay #AutismAcceptance #AutismSpectrumDisorder #GlobalEfforts #StemCellTherapy #StemCell #StemCellElegance #InnovativeWellness #RegenerativeMastery #HealthcareInnovation #regenerativemedicine #mesenchymalstemcell #RevolutionaryHealth #ScienceMeetsWellness #StemCellAdvancement #FutureOfMedicine #EmpowerYourHealth #WellnessEvolution #HealthcareExcellence